MaxxVision closes investment to launch new mammography product

TriMed Staff | | Health Imaging | Screening
MaxxVision LLC of Gainsville, Fla., a privately held developer of info-imaging systems, this week announced the closing of its second round of outside investment. The investment agreement signed with Emergent Growth Fund (Gainesville) includes $180,000 in funding for MaxxVision, providing working capital necessary to complete final design of its new iView FeatureFinder imaging device and bring the product to market in December.

iView is a lightweight, portable, handheld imaging device that enables physicians to perceive small, subtle features on mammography film images that may otherwise be overlooked.

TriMed Staff

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.